BOSTON SCIENTIFIC CORP (Form: 3, Received: 06/30/2025 16:51:56)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Monson Jonathan

2. Date of Event Requiring Statement (MM/DD/YYYY) 6/30/2025

3. Issuer Name and Ticker or Trading Symbol

BOSTON SCIENTIFIC CORP [BSX]

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
EVP and CFO /

(Street)

MARLBOROUGH, MA 01752-1234

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	34,727	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Stock Units	⁽¹⁾	2/12/2028 ⁽¹⁾	Common Stock	3,462 ⁽²⁾	⁽³⁾	D
Restricted Stock Units	⁽⁴⁾	2/13/2029 ⁽⁴⁾	Common Stock	7,066	⁽³⁾	D
Restricted Stock Units	⁽⁵⁾	2/14/2027 ⁽⁵⁾	Common Stock	2,116 ⁽⁶⁾	⁽³⁾	D
Restricted Stock Units	⁽⁷⁾	2/16/2026 ⁽⁷⁾	Common Stock	990 ⁽⁸⁾	⁽³⁾	D
Restricted Stock Units	⁽⁹⁾	8/2/2025 ⁽⁹⁾	Common Stock	1,090 ⁽¹⁰⁾	⁽³⁾	D
Restricted Stock Units	⁽¹¹⁾	12/1/2026 ⁽¹¹⁾	Common Stock	3,562	⁽³⁾	D
Stock Option (Right to Buy)	⁽¹²⁾	2/15/2028	Common Stock	12,004	$27.09	D
Stock Option (Right to Buy)	⁽¹³⁾	2/17/2031	Common Stock	14,299	$37.5	D
Stock Option (Right to Buy)	⁽¹⁴⁾	2/21/2029	Common Stock	8,605	$40.12	D
Stock Option (Right to Buy)	⁽¹⁵⁾	2/18/2030	Common Stock	10,346	$42.16	D
Stock Option (Right to Buy)	⁽¹⁶⁾	7/1/2029	Common Stock	10,692	$42.9	D
Stock Option (Right to Buy)	⁽¹⁷⁾	2/16/2032	Common Stock	13,180	$44.19	D
Stock Option (Right to Buy)	⁽¹⁸⁾	8/2/2031	Common Stock	15,503	$45.88	D
Stock Option (Right to Buy)	⁽¹⁹⁾	2/14/2033	Common Stock	12,702	$47.28	D
Stock Option (Right to Buy)	⁽²⁰⁾	12/1/2033	Common Stock	10,543	$56.14	D
Stock Option (Right to Buy)	⁽²¹⁾	2/12/2034	Common Stock	14,180	$64.99	D
Stock Option (Right to Buy)	⁽²²⁾	2/13/2035	Common Stock	7,165	$106.14	D

Explanation of Responses:
(1)	Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.
(2)	This amount represents the unvested portion of RSUs awarded on February 12, 2024, which will continue to vest in three remaining installments on the anniversary of the date of grant.
(3)	Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
(4)	Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.
(5)	Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.
(6)	This amount represents the unvested portion of RSUs awarded on February 14, 2023, which will continue to vest in two remaining installments on the anniversary of the date of grant.
(7)	Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.
(8)	This amount represents the unvested portion of RSUs awarded on February 16, 2022, which will continue to vest in one remaining installment on the anniversary of the date of grant.
(9)	Shares of common stock will be issued to the reporting person in four equal annual installments beginning on August 2, 2022, the first anniversary of the date of grant.
(10)	This amount represents the unvested portion of RSUs awarded on August 2, 2021, which will continue to vest in one remaining installment on the anniversary of the date of grant.
(11)	Shares of common stock will be issued to the reporting person in full on December 1, 2026, the third anniversary of the date of grant.
(12)	Grant to the reporting person of an option to purchase 12,004 shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.
(13)	Grant to the reporting person of an option to purchase 14,299 shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant.
(14)	Grant to the reporting person of an option to purchase 8,605 shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.
(15)	Grant to the reporting person of an option to purchase 10,346 shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant.
(16)	Grant to the reporting person of an option to purchase 10,692 shares of common stock vesting in four equal annual installments beginning on July 1, 2020, the first anniversary of the date of grant.
(17)	Grant to the reporting person of an option to purchase 13,180 shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.
(18)	Grant to the reporting person of an option to purchase 15,503 shares of common stock vesting in four equal annual installments beginning on August 2, 2022, the first anniversary of the date of grant.
(19)	Grant to the reporting person of an option to purchase 12,702 shares of common stock vesting in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.
(20)	Grant to the reporting person of an option to purchase 10,543 shares of common stock vesting in full on December 1, 2026, the third anniversary of the date of grant.
(21)	Grant to the reporting person of an option to purchase 14,180 shares of common stock vesting in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.
(22)	Grant to the reporting person of an option to purchase 7,165 shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.

Remarks:
monsonpoa.txt

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Monson Jonathan 300 BOSTON SCIENTIFIC WAY MARLBOROUGH, MA 01752-1234			EVP and CFO

Signatures
/s/ Susan Thompson, Attorney-in-Fact		6/30/2025
^**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

POWER OF ATTORNEY

Know all by these present that the undersigned hereby constitutes and appoints each of Vance R. Brown, Susan Thompson, Jonathan Robertson and Mary Wiseman signing singly, the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an executive officer and/or director of Boston Scientific Corporation (the "Company"), Form ID, Forms 3, 4 and 5, and amendments thereto, in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID, Form 3,4 or 5 and file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority;

(3) execute for and on behalf of the undersigned, in the undersigned's capacity as an executive officer and/or director of the Company, Forms 144 in accordance with Rule 144 of the Securities Exchange Act of 1933, as amended and the rules and regulations thereunder; and

(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 or Rule 144 of the Securities Act of 1933, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 and Forms 144 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 26 of June, 2025.

/s/ Jonathan R. Monson
_________________
Jonathan R. Monson